Spectrum Pharmaceuticals (Nasdaq: SPPI) announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE